The NDY1/KDM2B-miR-101-EZH2 axis has been identified as active in bladder cancer cells [32], wherein miR-101 suppresses the motility of T24 bladder cancer cells by targeting c-Met’s 3′-UTR [33]. Here, MET is linked to urinary bladder carcinoma.